Lung cancer Posts on Medivizor
Navigation Menu

Lung cancer Posts on Medivizor

Comparing the effectiveness and safety of chemotherapy-based combination therapies as first-line treatment for advanced non-small cell lung cancer with negative PD-L1.

Comparing the effectiveness and safety of chemotherapy-based combination therapies as first-line treatment for advanced non-small cell lung cancer with negative PD-L1.

Posted by on Oct 22, 2023 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of chemotherapy-based combination therapies for the treatment of patients with advanced non-small cell lung cancer (NSCLC) with negative PD-L1 expression. The data showed that pembrolizumab (Keytruda) plus chemotherapy combination was the best treatment regimen for improving overall survival...

Read More

How useful is thoracic tumor radiation in improving overall survival of patients with non-small-cell lung cancer and malignant pleural effusion?

How useful is thoracic tumor radiation in improving overall survival of patients with non-small-cell lung cancer and malignant pleural effusion?

Posted by on Sep 17, 2023 in Lung cancer | 0 comments

In a nutshell This study investigated the effect of thoracic tumor radiotherapy on overall survival (OS) in patients with metastatic non-small-cell lung cancer (NSCLC) with malignant pleural effusion (MPE). The authors concluded that thoracic tumor radiotherapy effectively improved OS with acceptable toxicity levels in these patients. Some background...

Read More

How safe and effective is prophylactic cranial irradiation in patients with extensive stage small cell lung cancer?

How safe and effective is prophylactic cranial irradiation in patients with extensive stage small cell lung cancer?

Posted by on Jul 30, 2023 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of prophylactic cranial irradiation (PCI) in patients with extensive stage (ES) small cell lung cancer (SCLC). The data indicated that PCI may decrease the occurrence of brain metastases in patients with ES-SCLC and improve 1-year survival time, without improving the overall survival...

Read More

Evaluating the long-term outcomes of nivolumab plus ipilimumab versus chemotherapy as first-line treatment for advanced non-small cell lung cancer.

Evaluating the long-term outcomes of nivolumab plus ipilimumab versus chemotherapy as first-line treatment for advanced non-small cell lung cancer.

Posted by on Jun 11, 2023 in Lung cancer | 0 comments

In a nutshell This evaluated the long-term outcomes of nivolumab (Opdivo) plus ipilimumab (Yervoy) versus chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC). The data showed that nivolumab plus ipilimumab increased the long-term overall survival versus chemotherapy in these patients. Some background NSCLC is the most...

Read More

Evaluating the effectiveness and safety of toripalimab in combination with chemotherapy as a first-line treatment for advanced NSCLC.

Evaluating the effectiveness and safety of toripalimab in combination with chemotherapy as a first-line treatment for advanced NSCLC.

Posted by on Apr 30, 2023 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of toripalimab (Tuoyi) in combination with chemotherapy as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). The data showed that toripalimab in combination with chemotherapy significantly improved overall survival and survival without cancer...

Read More

Evaluating the risk of cardiovascular side effects in cancer patients treated with PD-1/PD-L1 inhibitors.

Evaluating the risk of cardiovascular side effects in cancer patients treated with PD-1/PD-L1 inhibitors.

Posted by on Apr 30, 2023 in Lung cancer | 0 comments

In a nutshell This study evaluated the risk of cardiovascular (CV; heart and blood vessels) side effects in cancer patients treated with PD-1/PD-L1 inhibitors. The data showed that PD-1/PD-L1 inhibitors alone or combined with chemotherapy significantly increased the risk of CV side effects. PD-1/PD-L1 inhibitors combined with chemotherapy significantly...

Read More

Evaluating the effectiveness and safety outcomes of atezolizumab given before surgery in patients with non-small cell lung cancer.

Evaluating the effectiveness and safety outcomes of atezolizumab given before surgery in patients with non-small cell lung cancer.

Posted by on Mar 26, 2023 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of atezolizumab (Tecentriq) given before surgery for the treatment of patients with non-small cell lung cancer (NSCLC). The data showed that atezolizumab given before surgery was safe and effective for patients with NSCLC. Some background Non-small cell lung cancer (NSCLC)...

Read More

Evaluating the effectiveness and safety of cemiplimab plus chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer.

Evaluating the effectiveness and safety of cemiplimab plus chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer.

Posted by on Mar 5, 2023 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of cemiplimab (Libtayo) plus chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). The data showed that cemiplimab plus chemotherapy as first-line treatment was effective with manageable side effects in these patients. Some...

Read More

Comparing the effectiveness and safety between immune checkpoint inhibitors and docetaxel in patients with non-small cell lung cancer.

Comparing the effectiveness and safety between immune checkpoint inhibitors and docetaxel in patients with non-small cell lung cancer.

Posted by on Feb 27, 2023 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety between immune checkpoint inhibitors (ICIs) and docetaxel (Taxotere) therapy alone in patients with non-small cell lung cancer (NSCLC). The data showed ICIs significantly improved the survival outcomes with fewer serious side effects compared to docetaxel alone for the treatment of patients...

Read More

Evaluating the effectiveness and safety of different platinum-based chemotherapy regimens given after surgery for the treatment of early-stage resected NSCLC.

Evaluating the effectiveness and safety of different platinum-based chemotherapy regimens given after surgery for the treatment of early-stage resected NSCLC.

Posted by on Jan 3, 2023 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of different platinum-based chemotherapy regimens given after surgery for the treatment of early-stage resected non-small cell lung cancer (NSCLC). The authors concluded that the combination of cisplatin (Platinol)-vinorelbine (Nevelbine) improved the outcomes of these patients. Also, the...

Read More

Evaluating the effectiveness and safety of anlotinib as a third-line treatment in patients with advanced NSCLC.

Evaluating the effectiveness and safety of anlotinib as a third-line treatment in patients with advanced NSCLC.

Posted by on Dec 31, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of anlotinib (AL3818) as a third-line treatment in patients with advanced non-small cell lung cancer (NSCLC). The data showed that anlotinib as a third-line treatment was effective with manageable side effects in these patients. Some background NSCLC is the most common form of lung...

Read More

Evaluating the effectiveness and safety of ramucirumab and pembrolizumab versus standard of care in previously treated patients with advanced NSCLC.

Evaluating the effectiveness and safety of ramucirumab and pembrolizumab versus standard of care in previously treated patients with advanced NSCLC.

Posted by on Dec 9, 2022 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of ramucirumab (Cyramza) and pembrolizumab (Keytruda) versus standard of care (SOC) in previously treated patients with advanced non-small cell lung cancer (NSCLC). The data showed that ramucirumab and pembrolizumab significantly improved overall survival compared with SOC in...

Read More